SITE015-0186

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-10-15

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 134); relationship: Y; serious criteria: life-threatening

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 152); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-14 (study day 203); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-17 (study day 206); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-21 (study day 241); relationship: not assessed

Data queries

No data queries.